Home Bayer Advances Clinical-Stage IRAK4 Inhibitors Zabedosertib (BAY1834845) and BAY1830839 for Immune-Inflammatory Diseases

Bayer Advances Clinical-Stage IRAK4 Inhibitors Zabedosertib (BAY1834845) and BAY1830839 for Immune-Inflammatory Diseases

Mar 04, 2024 08:51 CST Updated 08:51
Bayer

Pharmaceutical Product R&D Developer